Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKrm22 Plc Regulatory News (KRM)

Share Price Information for Krm22 Plc (KRM)

Share Price is delayed by 15 minutes
Get Live Data
32.50    0.00 (0.00%)
Bid:
32.00
Ask:
33.00
Spread: 1.00 (3.125%)
Market Cap: £19.28m
KRM Live PriceLast checked at - London Stock Exchange

Intraday Krm22 Plc Share Chart

Trading Update

22 Jan 2025 07:00

RNS Number : 1752U
KRM22 PLC
22 January 2025
 

KRM22 plc

("KRM22", the "Group" or the "Company")

Trading Update

 

KRM22 plc, (AIM: KRM) the technology and software investment company with a particular focus on risk management in capital markets, today issues the following trading update for the 12 month period ended 31 December 2024 ("FY2024") with total revenue, Annual Recurring Revenue ("ARR") and adjusted EBITDA all slightly ahead of management's expectations.

 

The Company expects to report audited results for FY2024 in May 2025, and is pleased to report the following financial highlights*:

 

· ARR at 31 December 2024 of £6.6m (FY2023: £5.4m) - growth of 22.2%

New contracted ARR in the year of £1.7m (FY2023: £1.1m)

£1.2m of new contracted ARR generated from direct sales and £0.5m through the relationship with Trading Technologies International, Inc,

· Total revenue recognised of approximately £6.7m (FY2023: £5.3m) - growth of 26.4%

· Adjusted EBITDA: £0.9m (FY2023: loss of £1.4m)

· Gross cash as of 31 December 2024 of £1.0m (FY2023: £0.9m)

· Net debt at 31 December 2024 of £3.5m with the Company having drawn down a total of £4.5m on the debt facility with £0.5m remaining undrawn.

 

The Company has continued to execute on its plan to increase its ARR, delivering £6.6m ARR at FY2024, a net increase of £1.2m from £5.4m at the end of FY2023 and, as at the date of this announcement, the Company's ARR has further increased to £6.8m (£6.7m at FY2024 constant FX rates), with uplifts in contractual ARR from existing customers. The Company now has 44 institutional customers using its applications, of which seven customers have contracts in place for multiple applications.

 

The cost savings plan announced in the February 2024 trading update, with annual cost savings of approximately £1.2m, together with management continuing to tightly manage the cost base of the business and some additional non-recurring revenue has contributed to the Company reporting an adjusted EBITDA profit for FY2024 of £0.9m. 

 

The growth in ARR, continued management of the underlying cost base of the business and the Company's cash balance of £1.0m, together with the availability of £0.5m, which remains undrawn, under the TT convertible loan, means that the Company expects to continue to operate within its existing cash and debt facilities. 

 

Dan Carter, CEO commented: "The continued growth in ARR to £6.6m, surpassing management's expectations of 20% year on year growth, underscores KRM22's progress towards becoming a £10.0m ARR and cash profitable business. The sales pipeline of new opportunities remains strong, and we look forward to converting these opportunities in line with our expectations for 2025."

 

\* The financial expectations noted above are preliminary, and subject to year-end financial close and audit review processes.

 

 

For further information please contact:

 

KRM22 plc

Garry Jones, Chairman

Dan Carter, CEO

Kim Suter, CFO

 

InvestorRelations@krm22.com

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

Carl Holmes / Isaac Hooper / Rory Sale (Corporate Finance)

Sunila de Silva (ECM)

 

+44 (0)20 7220 0500

 

 

The information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended. With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

About KRM22 plc

KRM22 is a closed-ended investment company which listed on AIM on 30 April 2018. The Company has been established with the objective of creating value for its investors through the investment in, and subsequent growth and development of, target companies in the technology and software sector, with a focus on risk management in capital markets.

 

Through its investments and the Global Risk Platform, KRM22 helps capital market companies reduce the cost and complexity of risk management. The Global Risk Platform provides applications to help address firms' trading and corporate risk challenges and to manage their entire enterprise risk profile.

 

Capital markets companies' partner with KRM22 to optimise risk management systems and processes, improving profitability and expanding opportunities to increase portfolio returns by leveraging risk as alpha.

 

KRM22 plc is listed on AIM and the Group is headquartered in London, with offices in several of the world's major financial centres.

 

See more about KRM22 at KRM22.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSELFMFEISELF
Date   Source Headline
21st Jul 20237:00 amRNSDirector Dealing
20th Jul 20237:00 amRNSHalf Year Trading Update
4th Jul 20237:00 amRNSPosting of Accounts, Circular and Notice of GM
30th Jun 202312:41 pmRNSResult of AGM
27th Jun 20237:00 amRNSFinal Results
19th Jun 20237:00 amRNSNew Debt Facility
8th Jun 20237:00 amRNSAnnual Report and Notice of AGM
16th Dec 20223:15 pmRNSIssue of Options
20th Sep 20227:00 amRNSInterim Results
13th Jun 202210:00 amRNSHolding(s) in Company
5th May 202212:00 pmRNSResult of AGM
20th Apr 20222:30 pmRNSDirector Dealing
12th Apr 20227:00 amRNSNotice of AGM and Posting of Annual Report
7th Apr 20224:30 pmRNSHolding(s) in Company
28th Mar 20225:30 pmRNSHolding(s) in Company
23rd Mar 20227:00 amRNSFinal Results
15th Mar 20227:00 amRNSProduct Launch Under Distribution Agreement
1st Mar 20227:00 amRNSUpdate re Annual Results (Change of Date)
31st Jan 20227:00 amRNSTrading Update
5th Jan 202210:47 amRNSHolding(s) in Company
30th Dec 20219:47 amRNSSubscription Completion, Executive Changes and TVR
22nd Dec 20217:00 amRNSSubscription Update
22nd Nov 20217:00 amRNSHolding(s) in Company
1st Nov 20217:00 amRNSSubscription Agreement and Trading Update
20th Oct 20213:43 pmRNSHolding(s) in Company
16th Sep 20212:38 pmRNSDirector/PDMR Shareholding
13th Sep 20219:52 amRNSDirector/PDMR Shareholding
10th Sep 20212:48 pmRNSDirector/PDMR Shareholding
8th Sep 202112:00 pmRNSDirector/PDMR Shareholding
2nd Sep 20217:00 amRNSDirector/PDMR Shareholding
1st Sep 20217:00 amRNSInterim Results
30th Jul 20217:00 amRNSContract Extension
22nd Jul 20217:00 amRNSHalf Year Trading Update
24th Jun 20217:00 amRNSKRM22 announces partnership with Waymark Tech
28th Apr 20211:29 pmRNSResult of AGM
19th Apr 20217:00 amRNSExercise of options and total voting rights
26th Mar 20213:24 pmRNSHolding(s) in Company
23rd Mar 20218:00 amRNSNotice of AGM and Posting of Annual Report
18th Mar 20215:39 pmRNSHolding(s) in Company
16th Mar 202111:06 amRNSTechnology Demonstration
16th Mar 20217:00 amRNSFinal Results
24th Feb 20217:00 amRNSKRM22 announces new partnership
20th Jan 20217:00 amRNSDirector/PDMR Shareholding
13th Jan 20217:00 amRNSIssue of Options
12th Jan 20217:00 amRNSTrading Update
5th Oct 20207:00 amRNSIssue of Options
21st Sep 20208:33 amRNSIssue of Options
18th Sep 20209:26 amRNSHolding(s) in Company
16th Sep 20207:00 amRNSNew Debt Facility
16th Sep 20207:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.